US 12,167,994 B2
Vidofludimus for use in the treatment or prevention of viral diseases
Manfred Gröppel, Erlangen (DE); Daniel Vitt, Germering (DE); Hella Kohlhof, Munich (DE); and Andreas Mühler, Munich (DE)
Assigned to IMMUNIC AG, Gräfelfing (DE)
Filed by Immunic AG, Gräfelfing (DE)
Filed on Jul. 1, 2022, as Appl. No. 17/855,945.
Application 17/855,945 is a continuation of application No. 17/234,986, filed on Apr. 20, 2021, granted, now 11,376,232.
Claims priority of application No. 20170729 (EP), filed on Apr. 21, 2020; application No. 20184031 (EP), filed on Jul. 3, 2020; and application No. 21164552 (EP), filed on Mar. 24, 2021.
Prior Publication US 2022/0339132 A1, Oct. 27, 2022
Int. Cl. A61K 31/196 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/706 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/196 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 31/706 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07B 2200/13 (2013.01)] 19 Claims
 
1. A method of treating a long COVID symptom in a human subject in need thereof, comprising administering to the subject a compound according to Formula (I),

OG Complex Work Unit Chemistry
a pharmaceutically acceptable salt, a solvate, a solvate of a salt, a hydrate thereof.